Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3 domain-containing ring finger protein 2 (SH3RF2)
- Target
- SH3RF2
- Molecular classification
- E3 ubiquitin ligase, Enzyme, Protein phosphatase regulatory protein, Zinc finger protein (RING-type), Scaffold protein
01
Overview
SH3 domain-containing ring finger protein 2 (SH3RF2) is an E3 ubiquitin ligase characterized by an N-terminal RING finger domain and multiple SH3 domains. It acts as a multidomain scaffold protein, regulating cell signaling pathways such as the JNK pathway and controlling protein stability via the ubiquitin-proteasome system. SH3RF2 is involved in anti-apoptotic processes by stabilizing proteins like PAK4 through inhibition of their ubiquitination and proteasomal degradation. Overexpression of SH3RF2 is associated with increased cell survival, cancer progression, and chemoresistance, making it a putative therapeutic target and a candidate biomarker in oncology and other disease contexts.
- Other names
- E3 ubiquitin-protein ligase SH3RF2POSH-eliminating RING proteinRNF158PPP1R39POSHERHepp1Heart protein phosphatase 1-binding proteinProtein phosphatase 1 regulatory subunit 39RING finger protein 158RING-type E3 ubiquitin transferase SH3RF2SH3 domain-containing RING finger protein 2
02
Mechanism of action
Not specified for approved drugs; preclinical research points to oncogenic and anti-apoptotic modulation via inhibition of PAK4 ubiquitination and JNK pathway regulation
03
Biological functions
Ubiquitin-mediated protein degradationRegulation of protein metabolic processRegulation of PAK4 protein stabilityPositive regulation of JNK signaling pathwayRegulation of apoptosisInhibition of protein phosphatase 1 activityCellular stress response
04
Disease associations
Cancer (notably colon cancer, ovarian cancer)Chemoresistance (e.g., cisplatin resistance in ovarian cancer)Nonalcoholic fatty liver diseaseTuberculosis susceptibilityAutism spectrum disorder (associations reported)
05
Safety considerations
Targeting an anti-apoptotic, scaffolding ubiquitin ligase may affect normal tissue homeostasis and apoptosis regulation, potentially leading to adverse effects if systemically inhibited
06
Biomarkers
High SH3RF2 expression as a prognostic indicator for poor outcome in cancer, including colon cancerHigh SH3RF2 expression as a prognostic indicator for platinum resistance in ovarian cancer
Beyond the preview
Go deeper on SH3 domain-containing ring finger protein 2 (SH3RF2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SH3 domain-containing ring finger protein 2 (SH3RF2).